Bio-Techne (NASDAQ: TECH) reported Q4 EPS of $1.87, $0.17 better than the analyst estimate of $1.70. Revenue for the quarter came in at $259 million versus the consensus estimate of $244.62 million.

For earnings history and earnings-related data on Bio-Techne (TECH) click here.